SPERMOSENS Aktie

 

Spermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the exercise of warrants of series TO 5 (the “Warrants”). A total of 467,740,274 shares were subscribed for through the exercise of Warrants, corresponding to an exercise rate of 100 percent. Spermosens will receive proceeds of approximately SEK 2.6 million before transaction costs. The total number of outstanding Warrants amounted to 467,740,274. One (1) Warrant entitled the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.0055. The exercise period ran from 2 June 2025...

Spermosens AB ("Spermosens" or the "Company") today held its Annual General Meeting in Lund. The following resolutions were adopted: · The Annual Report and Auditor's Report for the financial year 2024 were presented. · CEO Tore Duvold provided a summary of the Company's operations and key developments over the past year. · The meeting resolved to adopt the income statement and balance sheet for 2024, and the Board of Directors was discharged from liability for the financial year. Election of Board of Directors and Auditor The meeting reelected the following members to the...

Spermosens AB (“Spermosens” or the “Company”) today announces that the Chairman of the Board, Ulrik Spork, and the CEO, Tore Duvold, have exercised their respective warrants of series TO5 for the subscription of new shares in the Company. Ulrik Spork has exercised 6,446,200 warrants, and Tore Duvold has exercised 5,750,000 warrants. The exercise of the warrants demonstrates continued confidence in Spermosens' revised strategy, the positive outcome of the clinical study and the long-term potential of the Company's proprietary diagnostic platform, JUNO-Checked. As previously...

Spermosens AB (“Spermosens” or the “Company”) today announces positive topline results from its clinical study conducted at the Reproductive Medicine Center (RMC) in Malmö. The study was designed to validate the diagnostic value of the Company's patented JUNO-Checked system and has now reached a successful conclusion. The results demonstrate a statistically significant correlation between the JUNO Score, a measurement of sperm binding to the JUNO receptor, and fertilization rate in IVF. Key results A total of 83 couples were recruited, and 66 semen samples were analyzed. Of these, 53...

On March 4, 2025 Spermosens announced that the company has secured a SEK 10.8 million strategic investment through a directed issue. The investment is fulfilling the capital need until mid-2026. At the same time, Spermosens assessed that the issue had to be notified according to the Act (2023:560) on the review of foreign direct investments. A notification was sent to the Inspectorate of Strategic Products. After review, the authority today informed Spermosens that it leaves the notification without further action, which basically is the same as approving the issue. During the review, the...

12 June 2025 is the last day of trading in warrants of series TO 5 in Spermosens AB (publ) (“Spermosens” or the “Company”). Subscription of shares by exercise of warrants of series TO 5 is ongoing until 16 June 2025. One (1) warrant of series TO 5 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.0055. The exercise period for the warrants of series TO 5 (the “Warrants”) began on 2 June 2025 and runs until 16 June 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.0055...

During the fourth quarter of 2024, Spermosens AB (publ) (“Spermosens” or the “Company”) carried out a rights issue of units with preferential rights for existing shareholders, as well as directed issues of units to a number of external investors, existing shareholders, and members of the Company's Board and management. Both the rights issue and the directed issues included units consisting of shares, warrants of series TO 5, and warrants of series TO 6. In connection with the directed issues, the Company also secured a credit facility under which the lender received warrants of series TO 5...

Spermosens hereby announces that the annual report for 2024 is now available for download on the company's website, www.spermosens.com. The annual report is also attached as a PDF to this press release. Please note that this version is an English translation of the official Swedish annual report (Årsredovisning) and has not been audited. As previously announced, the Annual General Meeting will be held on 16 June 2025. 2024 was a transformative year for Spermosens. The company implemented a revised strategy centered on generating strong clinical evidence for JUNO-Checked – its unique and...

Welcome to the Annual General Meeting of Spermosens AB, reg. no. 559179-0380, on June 16, 2025, at 10:00 PM at Scheeletorget 1, Medicon Village, The Spark, Lund. Registration for the meeting begins at 09:30 PM. A.         PARTICIPATION The right to participate in the Annual General Meeting is granted to shareholders who: - are registered in the share register maintained by Euroclear Sweden AB on June 5, 2025, and - have notified their intent to participate in the Annual General Meeting to the company at Spermosens AB, Medicon Village Scheeletorget 1, 223 81 Lund or via email: info@...

We have made solid progress during the first quarter, marked by positive interim results from our ongoing clinical study and the successful completion of financing to support our activities. JANUARY 1st – MARCH 31st 2025 SIGNIFICANT EVENTS DURING THE QUARTER    15-01-2025 Notice of Extraordinary General Meeting of Spermosens AB 17-02-2025 Announcement from the Extraordinary General Meeting of Spermosens AB (publ) on 17 February 2025 19-02-2025 Spermosens AB announces shareholding changes following latest directed issue 04-03-2025 Spermosens secures SEK 10.8 million strategic...

Spermosens AB ("Spermosens" or the "Company") provides an update on its ongoing clinical study, commercial discussions and financing. The clinical study at the Reproductive Medicine Center (RMC) in Malmö is progressing well, with 68 couples successfully recruited to date and JUNO binding analysis completed in 51 cases. The Company remains on track to achieve its clinical objectives and is confident it will complete the study by the end of 2025, or potentially earlier. Interim results to date continue to demonstrate a correlation between JUNO binding and fertilization outcomes, with the next...

Spermosens AB ("Spermosens" or the "Company") announces the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company´s patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first interim analysis released in December 2024. Specifically, the results continue to demonstrate correlation between the JUNO binding and fertility outcomes. To date, the study has successfully recruited 52 couples, with JUNO binding...

Spermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team's technology expertise is a key step in executing the Company's recently announced plan to achieve positive cash flow from the second half of 2026. Dr. Castillo-León, an expert in biosensors, microfluidics and lab-on-a-chip technologies, has joined...

Spermosens AB (publ) (“Spermosens” or the “Company”) announces a strategic collaboration with Scalania AG (“Scalania”), part of the UNITY Innovation Alliance, to accelerate the development and market readiness of its unique JUNO-Checked technology. Following the previous announcement on March 4th, 2025, the Company has now entered into a strategic collaboration agreement with Scalania, effective from April 2025. The collaboration is expected to provide key expertise to reinforce the development of JUNO-Checked technology, particularly in go-to-market strategy, regulatory processes and...

Spermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that a peer-reviewed article, “JUNO-Checked – A Live Cell Electrochemical Biosensor for Sperm Function Diagnostics,” has been published in the prestigious journal Sensors & Diagnostics by the Royal Society of Chemistry. This gold open-access journal is renowned for showcasing cutting-edge research on sensing technologies and diagnostic systems, with a particular focus on novel materials, innovative detection methods and advancements that enable in situ or real-world testing. The article details the groundbreaking...

Spermosens AB (publ) (“Spermosens” or the “Company”) presents the plan to achieve positive cash flow following a recent investment by a consortium of investors from Germany, Scandinavia and the United States. The plan includes completion of the ongoing clinical study and advancing the JUNO-Checked technology and system to ensure commercial viability. Through this approach, Spermosens aims to establish licensing agreements with leading players in the assisted reproductive technology (ART) market in the second half of 2026, positioning the company to achieve positive cash flow. As announced on...

Spermosens AB (publ) ("Spermosens" or the "Company") today announces the outcome of the TO3 series of warrants, issued in connection with the rights issue announced on 20 February 2024. The subscription price for the TO3 warrants was set at SEK 0.13, determined prior to the issuance of new shares in the rights issue completed in November 2024. The warrants were available for subscription until 17 April 2024 and could be exercised from 17 February 2025 to 3 March 2025, with the last day of trading on 27 February 2025. As the subscription price exceeded the prevailing market price, no...

Spermosens AB (publ) (“Spermosens” or the “Company”) has secured an investment of SEK 10.8 million through a directed issue from a consortium of American and European strategic investors. The investment, which does not include issuance of any warrants, provides funding until H2 2026, when the Company expects to reach cash flow positivity, primarily through income from license agreements with established partners in the global Assisted Reproductive Technology (ART) market. The Investment The Board of Directors has today, based on the authorization by the extraordinary general meeting on...

Spermosens AB ("Spermosens" or "the Company") announces that the last day of trading for the warrants of series TO3 on Spotlight Stock Market is 27 February 2025. The warrants of series TO3 were issued in connection with the rights issue announced on 20 February 2024, with a subscription period that ended on 17 April 2024. Each warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of 0.13 SEK. The exercise period for the warrants runs from 17 February 2025 to 3 March 2025. The subscription price of 0.13 SEK was determined before the issuance...

Aktieägarna i Spermosens AB (publ), org.nr 559179-0380 (”Bolaget”), kallas till extra bolagsstämma den 17 februari 2025 kl. 15.00 i Bolagets lokaler på Medicon Village Scheeletorget 1, 223 81 i Lund. Rätt att delta och anmälan   · dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som är den 7 februari 2025, · dels anmäla sig till stämman senast den 11 februari 2025. Anmälan görs per post till Spermosens AB, Medicon Village Scheeletorget 1, 223 81 Lund eller per e-post till info@spermosens.com.   I...